FIT Biotech Oy 
Company release 7.1.2019 at 9:55 EET

Changes in FIT Biotech's Board of Directors

FIT Biotech Oy's ("Company", FITBIO: FN Finland) Chairman of the Board of Directors, Doctor Chitra Bharucha has resigned from Board of Directors for medical reasons. Bharucha has served as a Chairman of FIT Biotech's Board of Directors since 2018 and as a member since 2016.

Chitra Bharucha comments: "FIT Biotech has a patented unique technology which will benefit patients with wide range of serious diseases and I am very disappointed that I have to leave the company at this time. I wish much success to FIT Biotech in commercialisation of the drug candidates."      

FIT Biotech's Board of Directors will elect its new Chairman from among its members in the meeting on 10 January 2019.

FIT Biotech Oy
Board of Directors

For further information:

CEO Erkki Pekkarinen
Tel: +358 44 027 0080

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

FIT Biotech in brief 

FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines. 

FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV.

FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.


Nasdaq Helsinki
Principal media